EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction

Takuro Saito iD, Mitsuru Saito, Ryohei Yamamoto, Ryuichiro Sagehashi, Yu Aoyama, Mizuki Mori, Chika Kajiwara, Kengo Furihata, Hideaki Kagaya, Hironobu Yagishita, Nobuhiro Fujiyama iD, Soki Kashima iD und 5 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Takuro Saito und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan. Hauptthemen laut MEDLINE: Everolimus, TOR Serine-Threonine Kinases, Signal Transduction, Kidney Transplantation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic allograft dysfunction, driven by interstitial fibrosis and tubular atrophy, remains a major cause of long-term renal allograft loss. Everolimus (EVR), a mammalian target of rapamycin (mTOR) inhibitor, may reduce fibrosis through antifibrotic effects and calcineurin inhibitor minimization. This study aimed to evaluate the impact of EVR-involving immunosuppression on renal allograft fibrosis and to identify predictors of fibrotic progression. A total of 104 living-donor kidney transplant recipients transplanted between 2011 and 2017 were retrospectively analyzed (EVR, n = 61; non-EVR, n = 43). Interstitial fibrosis was quantified in protocol biopsies using digital image analysis. Phosphorylation of the mTOR-signaling proteins p70 ribosomal S6 kinase and eukaryotic translation initiation factor 4E-binding protein 1 was assessed using a semiquantitative immunoreactive score. Multivariable regression analyses identified independent predictors of fibrotic progression. Cytomegalovirus infection was less frequent in the EVR group, whereas acute rejection, graft function, and graft survival were comparable between groups. At 1-year posttransplantation, interstitial fibrosis was significantly lower in the EVR group. EVR significantly suppressed p-4EBP1 phosphorylation and effectively modulated the mTOR-signaling pathway. Multivariable analysis identified the absence of EVR therapy as an independent predictor of accelerated fibrosis. EVR-involving immunosuppression attenuated renal interstitial fibrosis, likely through suppression of mTOR-signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusTOR Serine-Threonine KinasesSignal TransductionKidney TransplantationImmunosuppressive AgentsKidneyKidney DiseasesHumansFibrosisFemaleMalePhosphorylationGraft RejectionRetrospective StudiesImmunosuppression TherapyAdaptor Proteins, Signal TransducingGraft SurvivalCell Cycle Proteins

Stichwörter der Autor:innen

interstitial fibrosiskidney transplant outcomesliving kidney transplantationmammalian target of rapamycin inhibitormammalian target of rapamycin-related protein

Substanzen

EverolimusTOR Serine-Threonine KinasesImmunosuppressive AgentsMTOR protein, humanAdaptor Proteins, Signal TransducingEIF4EBP1 protein, humanCell Cycle Proteins

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
  • Division of Blood Purification, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
  • Center for Kidney Disease and Transplantation, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
  • Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
  • Clinical Research Promotion and Support Office, Future Cooperative Research Organization, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan.
  • Department of Renal and Urologic Surgery, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa 078-8510, Japan.

ORCID-Profile: Takuro Saito, Nobuhiro Fujiyama, Soki Kashima, Kazuyuki Numakura, Shintaro Narita, Masafumi Kikuchi, Masatomo Miura

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Saito, T., Saito, M., Yamamoto, R., Sagehashi, R., Aoyama, Y., Mori, M., Kajiwara, C., Furihata, K., Kagaya, H., Yagishita, H., Fujiyama, N., Kashima, S., Numakura, K., Narita, S., Kikuchi, M., Miura, M., & Habuchi, T. (2026). Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177634

Vancouver

Saito T, Saito M, Yamamoto R, Sagehashi R, Aoyama Y, Mori M, et al. Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177634

BibTeX
@article{Saito2026,
  author = {Saito, Takuro and Saito, Mitsuru and Yamamoto, Ryohei and Sagehashi, Ryuichiro and Aoyama, Yu and Mori, Mizuki and Kajiwara, Chika and Furihata, Kengo and Kagaya, Hideaki and Yagishita, Hironobu and Fujiyama, Nobuhiro and Kashima, Soki and Numakura, Kazuyuki and Narita, Shintaro and Kikuchi, Masafumi and Miura, Masatomo and Habuchi, Tomonori},
  title = {Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177634}
}
Kostenlos starten →